1. Phylogeny  
   Obscurin is a giant, modular protein encoded by the OBSCN gene that is evolutionarily conserved across vertebrate species. Its orthologs have been identified in invertebrates such as Caenorhabditis elegans, where the homologous protein UNC-89 shares many of the key domain features, and in Drosophila, underscoring a deep evolutionary origin for muscle giant proteins (grogan2019unravelingobscurinsin pages 1-3, perry2013obscurinsunassuminggiants pages 1-2). Comparative analyses of the domain architectures indicate that obscurin belongs to a family of cytoskeletal scaffold proteins that includes titin and nebulin, and it is evolutionarily related to kinases such as SPEG that also exhibit tandem myosin light chain kinase‐like domains. In addition, the presence of conserved immunoglobulin (Ig) and fibronectin type III (FnIII) domains in obscurin, along with its RhoGEF and dual kinase modules, highlights its critical role in muscle cell architecture and signaling – a feature that appears to have been maintained through more than 400 million years of vertebrate evolution (kontrogiannikonstantopoulos2009musclegiantsmolecular pages 28-29, taciroglu2025variantimpactprediction pages 72-76).
2. Reaction Catalyzed  
   Obscurin exhibits serine/threonine protein kinase activity, catalyzing the transfer of a phosphate group from ATP to target proteins on serine or threonine residues. The generalized chemical reaction can be written as:  
   ATP + [protein]-OH → ADP + [protein]-O-phosphate + H⁺ (grogan2020doublethetrouble pages 1-2).
3. Cofactor Requirements  
   The catalytic activity of obscurin, consistent with many serine/threonine kinases, is dependent on divalent metal ion cofactors. In particular, the presence of Mg²⁺ is required to facilitate the binding of ATP and proper positioning of the nucleotide for phosphoryl transfer (grogan2020doublethetrouble pages 1-2).
4. Substrate Specificity  
   Obscurin phosphorylates specific substrates through its kinase domains. Experimentally, only N-cadherin has been confirmed as a substrate in vitro, with the kinase domain of obscurin’s Kin1 responsible for the phosphorylation of its cytoplasmic tail, thereby influencing cell adhesion properties in cardiomyocytes (grogan2020doublethetrouble pages 10-11). In addition, by similarity and sequence conservation, obscurin is expected to phosphorylate the sodium/potassium‐transporting ATPase subunit ATP1B1, and this prediction is supported by its domain organization as an MLCK-like kinase (grogan2019unravelingobscurinsin pages 3-4). Apart from its catalytic role, obscurin contains a pleckstrin homology (PH) domain that confers selective binding to phosphatidylinositol lipids. The PH domain binds strongly to phosphatidylinositol 3,4‐bisphosphate [PtdIns(3,4)P₂] and phosphatidylinositol 4,5‐bisphosphate [PtdIns(4,5)P₂], and to a lesser extent to other phosphoinositides such as PtdIns(3)P, PtdIns(4)P, PtdIns(5)P, and PtdIns(3,4,5)P₃, thereby potentially influencing localization and membrane signaling events (hu2020proteomicanalysisof pages 1-2).
5. Structure  
   Obscurin is characterized by an extensive modular architecture that enables its diverse functions in muscle cells. The two principal isoforms described in mammals are obscurin-A (approximately 720 kDa) and obscurin-B (approximately 870 kDa). Obscurin-A is composed of a long array of immunoglobulin (Ig) domains – numbering around 59–65 – followed by a few fibronectin type III (FnIII) domains and a C-terminal nonmodular region containing binding sites for ankyrins (grogan2020doublethetrouble pages 1-2, perry2013obscurinsunassuminggiants pages 1-2). In contrast, obscurin-B includes, in addition to the N-terminal Ig and FnIII modules, two tandem serine/threonine kinase domains at its C-terminus; these kinase domains belong to the myosin light chain kinase (MLCK) family and are enzymatically active as evidenced by their autophosphorylation capabilities (grogan2019unravelingobscurinsin pages 6-8, grogan2020doublethetrouble pages 1-2).  
   Other notable structural features include a calmodulin-binding IQ motif, an Src homology 3 (SH3) domain, and a Rho guanine nucleotide exchange factor (RhoGEF) domain that is paired with a pleckstrin homology (PH) domain. The PH domain plays a key role in binding phosphoinositide lipids, while the RhoGEF domain is implicated in activating RhoA signaling cascades. Collectively, the linear arrangement of these domains over an extended amino acid chain (approaching 8000 residues in some isoforms) bestows upon obscurin the ability to act simultaneously as both a structural scaffold and an intracellular signaling molecule (hu2020proteomicanalysisof pages 1-2, kontrogiannikonstantopoulos2009musclegiantsmolecular pages 28-29, grogan2020doublethetrouble pages 1-2).
6. Regulation  
   Regulation of obscurin is multilayered and involves both its catalytic and scaffolding functions. The kinase domains inherent to obscurin – designated as Kin1 and Kin2 – are capable of autophosphorylation, a modification that may regulate their enzymatic activity. These phosphorylation events, which have been observed under conditions such as endurance exercise and electrically evoked muscle contractions, appear to modify the binding interactions and subcellular localization of obscurin (grogan2019unravelingobscurinsin pages 6-8, grogan2020doublethetrouble pages 10-11). In addition, obscurin activity is regulated at the transcriptional level by alternative promoter usage and extensive alternative splicing, generating multiple isoforms with distinct domain compositions and potentially divergent functions in various muscle types (kontrogiannikonstantopoulos2009musclegiantsmolecular pages 35-36, kontrogiannikonstantopoulos2019groganpflugersarchiv18.pdf pages 1-4). Furthermore, obscurin undergoes post-translational modifications – including phosphorylation at several sites distributed across its length – that may affect its stability, interaction with binding partners (such as titin and small ankyrin-1), and its role in mediating cytoskeletal and membrane dynamics (grogan2019unravelingobscurinsin pages 8-9, kontrogiannikonstantopoulos2019groganpflugersarchiv18.pdf pages 5-7).
7. Function  
   Obscurin serves dual functions as a structural component and as a signaling mediator in striated muscle. As a scaffold protein, it plays an essential role in myofibrillogenesis by coordinating the assembly of myosin into sarcomeric A bands and by linking the contractile apparatus to the sarcoplasmic reticulum and sarcolemma. Obscurin interacts directly with key sarcomeric proteins such as titin and myomesin, thereby contributing to the stability of the M-band and the overall organization of the sarcomere (grogan2019unravelingobscurinsin pages 1-3, kontrogiannikonstantopoulos2009musclegiantsmolecular pages 29-31). In addition, its binding to small ankyrin 1 through discrete sites at the C-terminus facilitates physical coupling between the sarcomere and the sarcoplasmic reticulum, which is critical for efficient excitation–contraction coupling (grogan2019unravelingobscurinsin pages 6-8, wang2018thickfilamentprotein pages 41-43).  
   From a signaling perspective, obscurin functions as a serine/threonine kinase that phosphorylates N-cadherin, thereby modulating cell–cell adhesion at the intercalated discs in cardiac muscle (grogan2020doublethetrouble pages 10-11). It is also implicated in the regulation of calcium cycling, through interactions that affect the activity of phospholamban and SERCA, and in the activation of RhoA through its RhoGEF domain, which may influence cytoskeletal organization and muscle hypertrophy (perry2013obscurinsunassuminggiants pages 2-4, grogan2019unravelingobscurinsin pages 4-6). Expression of obscurin is highest in striated muscles – particularly in the heart and skeletal muscle – although it is also present at lower levels in other tissues, reflecting its multifunctional roles in both structural maintenance and intracellular signal transduction (kontrogiannikonstantopoulos2009musclegiantsmolecular pages 35-36, hu2020proteomicanalysisof pages 1-2).
8. Other Comments  
   Mutations and altered expression of OBSCN have been linked to a range of pathological conditions. Inherited OBSCN variants, including missense, frameshift, and splicing mutations, have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy, and left ventricular noncompaction, where disruption of obscurin’s structural and signaling roles leads to impaired sarcomere organization and perturbed calcium handling (grogan2019unravelingobscurinsin pages 16-17, marston2017obscurinvariantsand pages 4-5). Furthermore, OBSCN is emerging as a potential contributor to oncogenic processes; reduced expression or loss of giant obscurins in epithelial tissues has been correlated with enhanced tumorigenicity and metastasis in cancers such as breast, colorectal, glioblastoma, and melanoma (grogan2019unravelingobscurinsin pages 8-9, perry2013obscurinsunassuminggiants pages 7-8). The alternative names Obscurin-RhoGEF and Obscurin-myosin light chain kinase reflect its dual capacity to mediate both GTPase activation and phosphorylation events, thereby integrating mechanical stability with dynamic signal transduction in muscle cells. Current research efforts advocate for comprehensive genetic screenings, detailed biochemical characterizations, and the development of preclinical animal models to further clarify the mechanistic contributions of OBSCN variants in muscle diseases and potentially in cancer, highlighting obscurin’s significance as a multifunctional protein central to both physiology and pathology (kontrogiannikonstantopoulos2019groganpflugersarchiv18.pdf pages 7-8, grogan2020doublethetrouble pages 11-11, taciroglu2025variantimpactprediction pages 141-144).

References

1. (grogan2019unravelingobscurinsin pages 1-3): Alyssa Grogan and Aikaterini Kontrogianni-Konstantopoulos. Unraveling obscurins in heart disease. Pflügers Archiv - European Journal of Physiology, 471:735-743, Aug 2019. URL: https://doi.org/10.1007/s00424-018-2191-3, doi:10.1007/s00424-018-2191-3. This article has 35 citations.
2. (grogan2019unravelingobscurinsin pages 3-4): Alyssa Grogan and Aikaterini Kontrogianni-Konstantopoulos. Unraveling obscurins in heart disease. Pflügers Archiv - European Journal of Physiology, 471:735-743, Aug 2019. URL: https://doi.org/10.1007/s00424-018-2191-3, doi:10.1007/s00424-018-2191-3. This article has 35 citations.
3. (grogan2019unravelingobscurinsin pages 4-6): Alyssa Grogan and Aikaterini Kontrogianni-Konstantopoulos. Unraveling obscurins in heart disease. Pflügers Archiv - European Journal of Physiology, 471:735-743, Aug 2019. URL: https://doi.org/10.1007/s00424-018-2191-3, doi:10.1007/s00424-018-2191-3. This article has 35 citations.
4. (grogan2019unravelingobscurinsin pages 6-8): Alyssa Grogan and Aikaterini Kontrogianni-Konstantopoulos. Unraveling obscurins in heart disease. Pflügers Archiv - European Journal of Physiology, 471:735-743, Aug 2019. URL: https://doi.org/10.1007/s00424-018-2191-3, doi:10.1007/s00424-018-2191-3. This article has 35 citations.
5. (grogan2019unravelingobscurinsin pages 8-9): Alyssa Grogan and Aikaterini Kontrogianni-Konstantopoulos. Unraveling obscurins in heart disease. Pflügers Archiv - European Journal of Physiology, 471:735-743, Aug 2019. URL: https://doi.org/10.1007/s00424-018-2191-3, doi:10.1007/s00424-018-2191-3. This article has 35 citations.
6. (grogan2020doublethetrouble pages 1-2): Alyssa Grogan, Panagiotis Tsakiroglou, and Aikaterini Kontrogianni-Konstantopoulos. Double the trouble: giant proteins with dual kinase activity in the heart. Biophysical Reviews, 12:1019-1029, Jul 2020. URL: https://doi.org/10.1007/s12551-020-00715-3, doi:10.1007/s12551-020-00715-3. This article has 16 citations and is from a peer-reviewed journal.
7. (grogan2020doublethetrouble pages 10-11): Alyssa Grogan, Panagiotis Tsakiroglou, and Aikaterini Kontrogianni-Konstantopoulos. Double the trouble: giant proteins with dual kinase activity in the heart. Biophysical Reviews, 12:1019-1029, Jul 2020. URL: https://doi.org/10.1007/s12551-020-00715-3, doi:10.1007/s12551-020-00715-3. This article has 16 citations and is from a peer-reviewed journal.
8. (hu2020proteomicanalysisof pages 1-2): Li-Yen R. Hu and Aikaterini Kontrogianni-Konstantopoulos. Proteomic analysis of myocardia containing the obscurin r4344q mutation linked to hypertrophic cardiomyopathy. Frontiers in Physiology, May 2020. URL: https://doi.org/10.3389/fphys.2020.00478, doi:10.3389/fphys.2020.00478. This article has 17 citations and is from a peer-reviewed journal.
9. (kontrogiannikonstantopoulos2009musclegiantsmolecular pages 28-29): Aikaterini Kontrogianni-Konstantopoulos, Maegen A. Ackermann, Amber L. Bowman, Solomon V. Yap, and Robert J. Bloch. Muscle giants: molecular scaffolds in sarcomerogenesis. Physiological Reviews, 89:1217-1267, Oct 2009. URL: https://doi.org/10.1152/physrev.00017.2009, doi:10.1152/physrev.00017.2009. This article has 341 citations and is from a highest quality peer-reviewed journal.
10. (kontrogiannikonstantopoulos2009musclegiantsmolecular pages 35-36): Aikaterini Kontrogianni-Konstantopoulos, Maegen A. Ackermann, Amber L. Bowman, Solomon V. Yap, and Robert J. Bloch. Muscle giants: molecular scaffolds in sarcomerogenesis. Physiological Reviews, 89:1217-1267, Oct 2009. URL: https://doi.org/10.1152/physrev.00017.2009, doi:10.1152/physrev.00017.2009. This article has 341 citations and is from a highest quality peer-reviewed journal.
11. (kontrogiannikonstantopoulos2019groganpflugersarchiv18.pdf pages 1-4): A Kontrogianni-Konstantopoulos. Groganpflugersarchiv’18. pdf. Unknown journal, 2019.
12. (kontrogiannikonstantopoulos2019groganpflugersarchiv18.pdf pages 5-7): A Kontrogianni-Konstantopoulos. Groganpflugersarchiv’18. pdf. Unknown journal, 2019.
13. (kontrogiannikonstantopoulos2019groganpflugersarchiv18.pdf pages 7-8): A Kontrogianni-Konstantopoulos. Groganpflugersarchiv’18. pdf. Unknown journal, 2019.
14. (marston2017obscurinvariantsand pages 4-5): Steven Marston. Obscurin variants and inherited cardiomyopathies. Biophysical Reviews, 9:239-243, May 2017. URL: https://doi.org/10.1007/s12551-017-0264-8, doi:10.1007/s12551-017-0264-8. This article has 40 citations and is from a peer-reviewed journal.
15. (perry2013obscurinsunassuminggiants pages 1-2): Nicole A. Perry, Maegen A. Ackermann, Marey Shriver, Li‐Yen R. Hu, and Aikaterini Kontrogianni‐Konstantopoulos. Obscurins: unassuming giants enter the spotlight. IUBMB Life, Jun 2013. URL: https://doi.org/10.1002/iub.1157, doi:10.1002/iub.1157. This article has 50 citations and is from a peer-reviewed journal.
16. (perry2013obscurinsunassuminggiants pages 2-4): Nicole A. Perry, Maegen A. Ackermann, Marey Shriver, Li‐Yen R. Hu, and Aikaterini Kontrogianni‐Konstantopoulos. Obscurins: unassuming giants enter the spotlight. IUBMB Life, Jun 2013. URL: https://doi.org/10.1002/iub.1157, doi:10.1002/iub.1157. This article has 50 citations and is from a peer-reviewed journal.
17. (perry2013obscurinsunassuminggiants pages 7-8): Nicole A. Perry, Maegen A. Ackermann, Marey Shriver, Li‐Yen R. Hu, and Aikaterini Kontrogianni‐Konstantopoulos. Obscurins: unassuming giants enter the spotlight. IUBMB Life, Jun 2013. URL: https://doi.org/10.1002/iub.1157, doi:10.1002/iub.1157. This article has 50 citations and is from a peer-reviewed journal.
18. (taciroglu2025variantimpactprediction pages 141-144): A Taciroğlu. Variant impact prediction in the obscurin and trio protein families through evolutionary conservation and structural analysis. Unknown journal, 2025.
19. (grogan2019unravelingobscurinsin pages 16-17): Alyssa Grogan and Aikaterini Kontrogianni-Konstantopoulos. Unraveling obscurins in heart disease. Pflügers Archiv - European Journal of Physiology, 471:735-743, Aug 2019. URL: https://doi.org/10.1007/s00424-018-2191-3, doi:10.1007/s00424-018-2191-3. This article has 35 citations.
20. (grogan2020doublethetrouble pages 11-11): Alyssa Grogan, Panagiotis Tsakiroglou, and Aikaterini Kontrogianni-Konstantopoulos. Double the trouble: giant proteins with dual kinase activity in the heart. Biophysical Reviews, 12:1019-1029, Jul 2020. URL: https://doi.org/10.1007/s12551-020-00715-3, doi:10.1007/s12551-020-00715-3. This article has 16 citations and is from a peer-reviewed journal.
21. (kontrogiannikonstantopoulos2009musclegiantsmolecular pages 29-31): Aikaterini Kontrogianni-Konstantopoulos, Maegen A. Ackermann, Amber L. Bowman, Solomon V. Yap, and Robert J. Bloch. Muscle giants: molecular scaffolds in sarcomerogenesis. Physiological Reviews, 89:1217-1267, Oct 2009. URL: https://doi.org/10.1152/physrev.00017.2009, doi:10.1152/physrev.00017.2009. This article has 341 citations and is from a highest quality peer-reviewed journal.
22. (taciroglu2025variantimpactprediction pages 72-76): A Taciroğlu. Variant impact prediction in the obscurin and trio protein families through evolutionary conservation and structural analysis. Unknown journal, 2025.
23. (wang2018thickfilamentprotein pages 41-43): Li Wang, Janelle Geist, Alyssa Grogan, Li‐Yen R. Hu, and Aikaterini Kontrogianni‐Konstantopoulos. Thick filament protein network, functions, and disease association. Comprehensive Physiology, 8 2:631-709, Mar 2018. URL: https://doi.org/10.1002/cphy.c170023, doi:10.1002/cphy.c170023. This article has 90 citations and is from a peer-reviewed journal.